Skip to content
C2N Diagnostics logo — Fierce Medtech named C2N one of its Fierce 15 for 2020; "one...

C2N Diagnostics

Fierce Medtech named C2N one of its Fierce 15 for 2020; "one of the most promising private companies in the industry.”

Founded 2007 United States United States 92 employees Corporate Round Total: $52.20M Biotechnology

General Information

Company Name C2N Diagnostics
Founded Year 2007
Location United States United States
Employees 92
Industries Biotechnology
Funding Stage Corporate Round
Social

BounceWatch is an independent company data service, not affiliated with C2N Diagnostics. To contact C2N Diagnostics, visit c2ndiagnostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does C2N Diagnostics compare?

A PDF of C2N Diagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting C2N Diagnostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About C2N Diagnostics

C2N Diagnostics, established in 2007 and headquartered in the United States, is a biotechnology startup making significant strides in the medical industry. The company's dedication to innovation and excellence has been acknowledged by Fierce Medtech, which named C2N one of its Fierce 15 for 2020, recognizing it as "one of the most promising private companies in the industry." C2N Diagnostics is committed to bringing Clarity Through Innovation™ to the forefront of therapeutic discovery and diagnostics for human neurological disorders. Its flagship product, the PrecivityAD™ blood test, employs mass spectrometry to measure multiple analytes in the blood, including Aβ42, Aβ40, and apolipoprotein E isoforms. While not a standalone diagnostic tool for Alzheimer's disease, it serves as a crucial aid for physicians in the evaluation process, predicting brain amyloid plaques as determined by PET scan results. Notably, the test has received a Breakthrough Device Designation from the U.S. Food and Drug Administration and has achieved the CE Mark from the European Union. C2N's steadfast commitment to advancing brain health monitoring through accessible and cost-effective blood tests has not gone unnoticed. In March 2024, the company secured a remarkable $15.00M corporate round investment from Eisai US, endorsing its pioneering efforts in revolutionizing neurological disorder diagnostics and therapeutic discovery. For further details, visit www.C2N.com.

Business keywords: Medtech, Diagnostics, Therapeutic Discovery, Neurological Disorders, Blood Tests, Alzheimer’s Disease, Precision Medicine, Mass Spectrometry, Health Care, FDA Breakthrough Device, CE Mark, Protein Diagnostics, Neurodegeneration, Research and Development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Corporate Round $15.00M 1
Eisai US
06 Mar 2024
Venture Round $15.00M 1
GHR Foundation
16 Feb 2023
Grant $2.20M 1
Alzheimer's Drug Discovery Foundation
24 Sep 2020
Venture Round $20.00M 1
GHR Foundation
15 May 2020

C2N Diagnostics Alternatives & Competitors

View All Alternatives
C2N Diagnostics vs
Olaris, Inc
Olaris, Inc United States

Removing the Guesswork from Medicine

Series B
16 employees
Biopharma, Biotechnology
C2N Diagnostics vs

Automating precision in clinical diagnostics with innovative chromatography-mass spectrometry system...

Seed
Biotechnology
C2N Diagnostics vs

La ciencia si no es honesta, no es ciencia. Dr. Manuel Sarasa.

Venture round
22 employees
Biopharma, Biotechnology

FAQ About C2N Diagnostics

Fierce Medtech named C2N one of its Fierce 15 for 2020; "one of the most promising private companies in the industry.”
C2N Diagnostics was founded in 2007.
C2N Diagnostics is headquartered in United States.
C2N Diagnostics operates in Biotechnology. Its work centres on Medtech, Diagnostics, Therapeutic Discovery and Neurological Disorders.
C2N Diagnostics has approximately 92 employees.
C2N Diagnostics has completed 4 funding rounds, raising a total of $52.20M. The latest funding stage is Corporate Round.
Top alternatives and competitors to C2N Diagnostics include Olaris, Inc, Adima Technology, Araclon Biotech, S.L., InterVenn Biosciences, Adaptive Biotechnologies Corp.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
C2N Diagnostics and Olaris, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for C2N Diagnostics, https://bouncewatch.com/company/c2n-diagnostics, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout